BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen.
PF 04929113 can be used in pharmacological activity and therapeutic use in therapeutic breast cancer drug target for multiclass comparative virtual screening to identify novel Hsp90 inhibitors. HSP90
Enzyminhibitor
This potent and selective HSP90 inhibitor (FW = 521.54 g/mol; CAS 908115-27-5; Solubility: 100 mg/mL DMSO, <1mg/mL H2O), also knownas SNX-5422 and (1R,4R)-4-(2-carbamoyl-5-(6,6-dimethyl-4-oxo-3- (trifluoromethyl)-4,5,6,7-tetrahydroindazol-1-yl)phenylamino)cyclohexyl 2- aminoacetate, targets heat shock protein-90 (Kd = 41 nM) and also inhibits Her-2 degradation (IC50 = 37 nM). PF-04929113 also shows potent antiproliferative activity against a broad range of cancer cell types, e.g. MCF-7 (IC50 =16 nM), SW620 (IC50 =19 nM), K562 (IC50 =23 nM), SK-MEL-5 (IC50 =25 nM), and A375 (IC50 =51 nM). SNX2112 inhibits in vitro proliferation, inducing G2/M arrest, and enhanced cytotoxicity, chemosensitivity, and radiosensitivity between 25 and 250 nM, decreasing expression and/or phosphorylation of EGFR, c-MET, AKT, ERK-1 and -2, IκB kinase, and STAT3, corresponding downstream NFκB, AP-1, and STAT3 reporter genes, and target oncogenes and angiogenic cytokines.
PF-04929113 Upstream-Materialien And Downstream Produkte